权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Excessive Sleepiness in Preclinical Alzheimer's Disease

临床前阿尔茨海默病的过度嗜睡

基本信息

批准号：
9897520
负责人：
David T Plante
金额：
$ 15.5万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2022-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9897520
关键词：
Address Adult Aging Alleles Alzheimer&apos s Disease Alzheimer&apos s disease pathology Alzheimer&apos s disease risk Alzheimer’s disease biomarker Amyloid Amyloid beta-Protein Amyloid deposition Apolipoprotein E Area Biological Markers Brain Brain region Cerebrospinal Fluid Cognitive deficits Conscious Data Dementia Deposition Development Disease Drowsiness Epidemic Excessive Daytime Sleepiness Functional disorder General Population Impaired cognition Individual Inferior Institutes Investigation Lead Link Longitudinal Studies Maps Measures Neuraxis Neurons Parietal Parietal Lobe Participant Pathologic Processes Pathology Pattern Persons Phase Phenotype Population Prevention strategy Process Public Health Reaction Time Research Research Project Grants Resources Risk Role Site Sleep Sleep Apnea Syndromes Structure Structure of supramarginal gyrus Symptoms System Testing Therapeutic Wisconsin Work abeta deposition aged alertness cingulate cortex cohort dementia risk experience improved indexing locus ceruleus structure middle age nervous system disorder neurobehavioral neuroimaging neurophysiology non-demented noradrenergic pre-clinical prospective response screening tau Proteins tau mutation treatment strategy vigilance β-amyloid burden

项目摘要

PROJECT SUMMARY/ABSTRACT Alzheimer's Disease (AD) is one of the most devastating neurological disorders, and is reaching epidemic proportions in the context of an aging U.S. population. Current treatment strategies have minimal impact and only slow the progression of the disorder once cognitive deficits are established. Thus, there is a clear need to identify persons at risk for AD pathology during the preclinical phase of the disorder, so that preventative strategies can be developed. Multiple emerging lines of research suggest excessive daytime sleepiness is a key precognitive symptom related to the Alzheimer's continuum. However, daytime somnolence is experienced by a large proportion of the general population, and is a non-specific symptom that can reflect myriad changes in brain function. To further advance this area of research, this project will clarify how specific objective measures of sleepiness are associated with AD biomarkers in the preclinical phase of the disorder. This study will address two Specific Aims and three related hypotheses targeted towards this vital area of inquiry. First, it will verify specific objective measures of sleepiness that map to increased β-amyloid in brain regions susceptible to early deposition in preclinical AD. Specifically, it will build on preliminary findings that suggest infrared pupillometry, a measure of noradrenergic tone in the locus coeruleus, is reflective of increased β-amyloid burden in the supramarginal gyrus. Additionally, it will test the hypothesis that a specific measure of daytime somnolence, the mean reaction time during the slowest 10% of responses on the psychomotor vigilance task, which has been previously connected to activity in the default mode network, will be associated with β-amyloid deposition in the precuneus/posterior cingulate cortex, a key constituent of this network. Finally, this investigation will clarify whether phosphorylated and total tau protein in the cerebrospinal fluid are associated with findings from infrared pupillometry as hypothesized, given the locus coeruleus is the earliest site of abnormal tau deposition observed in AD. This research will be conducted in 75 well- characterized middle to older-aged adults participating in Wisconsin Alzheimer's Disease Research Center studies, and will leverage previously collected neuroimaging and biospecimen data, combined with prospective assessment of daytime sleepiness, longitudinal sleep-wake patterns, and sleep-related breathing disorders, to perform robust and well-controlled analyses. Addressing the Specific Aims of this application will have a sizeable impact on AD and sleep research, by linking measureable sleepiness phenotypes to associated pathological processes in the brain in preclinical AD. In so doing, this project will advance this vital area of inquiry in preclinical AD, that may lead to the development of improved screening and preventative therapeutic strategies for the disease.

项目总结/摘要阿尔茨海默病（Alzheimer's Disease，AD）是一种严重的神经系统疾病，目前正逐渐成为一种流行病在美国人口老龄化的背景下。目前的治疗策略影响甚微，只会在认知缺陷形成后减缓疾病的发展因此，显然需要在疾病的临床前阶段识别处于AD病理学风险中的人，可以制定战略。多项新的研究表明，白天过度嗜睡是一种与阿尔茨海默氏症相关的关键性脑卒中症状然而，白天嗜睡是大部分普通人群都经历过，并且是一种非特异性症状，可以反映大脑功能的无数变化为了进一步推进这一领域的研究，该项目将阐明如何具体嗜睡的客观测量与疾病临床前阶段的AD生物标志物相关。本研究将针对这一重要领域提出两个具体目标和三个相关假设，查询首先，它将验证与大脑中β-淀粉样蛋白增加相关的嗜睡的具体客观测量方法在临床前AD中易受早期沉积影响的区域。具体而言，它将以初步调查结果为基础，表明红外瞳孔测量，蓝斑去甲肾上腺素能张力的测量，是反映边缘上回β淀粉样蛋白负荷增加。此外，它将测试假设，一个特定的白天嗜睡的测量，在最慢的10%的反应的平均反应时间，心理警戒任务，这是以前连接到活动的默认模式网络，将与楔前叶/后扣带回皮质中的β-淀粉样蛋白沉积有关，这是这一过程的关键组成部分。网络最后，这项研究将阐明脑脊髓中磷酸化的和总的tau蛋白是否与脑脊髓中的tau蛋白有关。液体与红外瞳孔测量的结果相关，因为假设蓝斑是在AD中观察到的异常tau沉积的最早位点。这项研究将在75口井中进行- 参加威斯康星州阿尔茨海默病研究中心的中老年人研究，并将利用以前收集的神经成像和生物标本数据，结合前瞻性评估日间嗜睡、纵向睡眠-觉醒模式和睡眠相关呼吸障碍，进行稳健且受控良好的分析。解决这个应用程序的具体目标将有一个对AD和睡眠研究产生了相当大的影响，通过将可测量的嗜睡表型与在临床前AD的大脑中的病理过程。通过这样做，该项目将推动这一重要领域的发展，在临床前AD的调查，这可能会导致改善筛选和预防性治疗的发展疾病的战略。